<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2025-29-4-22-36</article-id><article-id custom-type="edn" pub-id-type="custom">MUTQZV</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-2492</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ И ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS AND LECTURES</subject></subj-group></article-categories><title-group><article-title>Мелатонин в патогенезе и лечении хронической болезни почек</article-title><trans-title-group xml:lang="en"><trans-title>Melatonin in the pathogenesis and treatment of chronic kidney disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7325-8027</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ованесов</surname><given-names>К. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Ovanesov</surname><given-names>K. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Ованесов Карэн Борисович, д-р мед. наук</p><p>195067, Санкт-Петербург, Пискаревский пр., д. 47</p><p>Тел.: +7(962)-454-91-88</p></bio><bio xml:lang="en"><p>Prof. Karen B. Ovanesov, MD, PhD, DMedSci</p><p>195067, St. Petersburg, Piskarevsky pr., 47</p></bio><email xlink:type="simple">ovanesov2007@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1745-6982</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колмакова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolmakova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доц. Колмакова Елена Валерьевна, канд. мед. наук</p><p>195067, Санкт-Петербург, Пискаревский пр., д. 47</p><p>Тел.: +7(981)-120-13-10</p></bio><bio xml:lang="en"><p>Associate prof. Elena V. Kolmakova, MD, PhD</p><p>195067, St. Petersburg, Piskarevsky pr., 47</p><p>Phone: +7(962)-454-91-88</p></bio><email xlink:type="simple">Elena.Kolmakova@szgmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4075-4096</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бакулина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bakulina</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Бакулина Наталья Валерьевна, д-р мед. наук</p><p>195067, Санкт-Петербург, Пискаревский пр., д. 47</p><p>Тел.: +7(906)-240-55-55</p></bio><bio xml:lang="en"><p>Prof. Natalia V. Bakulina, MD, PhD, DMedSci</p><p>195067, St. Petersburg, Piskarevsky pr., 47</p><p>Phone: +7(906)-240-55-55</p></bio><email xlink:type="simple">Bakulina@szgmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Северо-Западный государственный медицинский университет им. И.И. Мечникова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North-Western State Medical University named after I.I. Mechnikov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>01</month><year>2026</year></pub-date><volume>29</volume><issue>4</issue><fpage>22</fpage><lpage>36</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ованесов К.Б., Колмакова Е.В., Бакулина Н.В., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Ованесов К.Б., Колмакова Е.В., Бакулина Н.В.</copyright-holder><copyright-holder xml:lang="en">Ovanesov K.B., Kolmakova E.V., Bakulina N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/2492">https://journal.nephrolog.ru/jour/article/view/2492</self-uri><abstract><p>Хроническая болезнь почек (ХБП) широко распространена и встречается у 10–13 % населения планеты. К примеру, только в США, по последним данным, заболевание диагностировано у 37 миллионов взрослых пациентов. При такой патологии страдают физиологические и биологические механизмы гомеостаза (баланс электролитов и pH, регуляция артериального давления и эндокринной сферы, выведение токсинов, метаболические нарушения). Заболевание необратимо, на начальных этапах протекает бессимптомно, постепенно прогрессирует, и нарушения гомеостаза становятся клинически значимыми. На начальных этапах проводится консервативная нефропротективная терапия. На поздних этапах появляется потребность в заместительной терапии (гемодиализ, перитонеальный диализ и трансплантация почки). Целью консервативного лечения ХБП является замедление прогрессирования почечной патологии, а также коррекция возникающих осложнений со стороны других органов и систем организма (метаболические состояния, сердечно-сосудистые нарушения, анемии и др.). Разработанные сегодня алгоритмы лечения ХБП, к сожалению, не решают всех вопросов и заставляют искать новые, дополнительные подходы к коррекции определенных патологических процессов при ХБП. Именно с фармакотерапевтических позиций в последние годы привлекает к себе внимание мелатонин (МТ), у которого показана способность ограничивать большинство проявлений ХБП. Цель данного обзора – обобщить информацию о потенциальных возможностях применения МТ при ХБП, учитывая его позитивное влияние на сердечно-сосудистую систему, диабет, гомеостаз и ряд других состояний, сопутствующих почечной патологии.</p></abstract><trans-abstract xml:lang="en"><p>Chronic kidney disease (CKD) is widespread and occurs in 10-13 % of the world's population. For example, in the United States alone, according to the latest data, 37 million adult patients have been diagnosed with the disease. With this pathology, the physiological and biological mechanisms of homeostasis are affected (electrolyte and pH balance, regulation of blood pressure and the endocrine system, elimination of toxins, and metabolic disorders). The disease is irreversible, asymptomatic at the initial stages, gradually progresses and homeostasis disorders become clinically significant. Conservative nephroprotective therapy is performed at the initial stages. In the later stages, there is a need for replacement therapy (hemodialysis, peritoneal dialysis and kidney transplantation). The goal of conservative treatment of CKD is to slow the progression of renal pathology, as well as to correct complications from other organs and body systems (metabolic conditions, cardiovascular disorders, anemia, etc.). Unfortunately, the algorithms developed today for the treatment of CKD do not solve all the issues and force us to look for new, additional approaches to correcting certain pathological processes in CKD. It is from a pharmacotherapeutic perspective that melatonin (MT) has attracted attention in recent years, showing its ability to limit most manifestations of CKD. The purpose of this review is to summarize information about the potential use of MT in CKD, taking into account its positive effect on the cardiovascular system, diabetes, homeostasis, and a number of other conditions associated with renal pathology.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>мелатонин</kwd><kwd>хроническая болезнь почек</kwd><kwd>диабетическая нефропатия</kwd><kwd>тубулоинтерстициальный нефрит</kwd><kwd>терминальная почечная недостаточность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>melatonin</kwd><kwd>chronic kidney disease</kwd><kwd>diabetic nephropathy</kwd><kwd>tubulointerstitial nephritis</kwd><kwd>end stage renal disease</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Арушанян ЭБ, Батурин ВА, Ованесов КБ. Основы хрономедицины и хронофармакологии. Ставрополь: Ставропольский государственный медицинский университет, 2016. ISBN 978-5-89822-436-3</mixed-citation><mixed-citation xml:lang="en">Arushanyan EB, Baturin VA, Ovanesov KB. Fundamentals of Chronomedicine and Chronopharmacology. Stavropol: Stavropol State Medical University; 2016. ISBN 978-5-89822-436-3</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Арушанян ЭБ, Бейер ЭВ. Мелатонин: биология, фармакология, клиника. Ставрополь: Ставропольский государственный медицинский университет, 2015. ISBN 978-5-89822-400-4</mixed-citation><mixed-citation xml:lang="en">Arushanyan EB, Beyer EV. Melatonin: Biology, Pharmacology, Clinic. Stavropol: Stavropol State Medical University; 2015. ISBN 978-5-89822-400-4</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Okamoto HH, Cecon E, Osamu Nureki, Rivara S, Jockers R. Melatonin receptor structure and signaling. Journal of pineal research 2024;76(3). doi: https://doi.org/10.1111/jpi.12952</mixed-citation><mixed-citation xml:lang="en">Okamoto HH, Cecon E, Osamu Nureki, Rivara S, Jockers R. Melatonin receptor structure and signaling. Journal of pineal research 2024;76(3). doi:https://doi.org/10.1111/jpi.12952</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Jaroslav Hrenak, Paulis L, Repova K et al. Melatonin and Renal Protection: Novel Perspectives from Animal Experiments and Human Studies (Review). Current Pharmaceutical Design 2014;21(7):936–949. doi: https://doi.org/10.2174/1381612820666140929092929</mixed-citation><mixed-citation xml:lang="en">Jaroslav Hrenak, Paulis L, Repova K et al. Melatonin and Renal Protection: Novel Perspectives from Animal Experiments and Human Studies (Review). Current Pharmaceutical Design 2014;21(7):936–949. doi:https://doi.org/10.2174/1381612820666140929092929</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Арушанян Э, Ованесов К. Значение мелатонина для деятельности почек. Медицинские новости Северного Кавказа 2018;13(1). doi: https://doi.org/10.14300/mnnc.2018.13034</mixed-citation><mixed-citation xml:lang="en">Arushanyan E, Ovanesov K. Significance of melatonin for reneal activity. Medical news of the North Caucasus 2018;13(1). doi:https:// doi.org/10.14300/mnnc.2018.13034</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Theofilis P, Vordoni A, Kalaitzidis RG. The Role of Melatonin in Chronic Kidney Disease and Its Associated Risk Factors: A New Tool in Our Arsenal? American Journal of Nephrology 2022;53(7):565–574. doi: https://doi.org/10.1159/000525441</mixed-citation><mixed-citation xml:lang="en">Theofilis P, Vordoni A, Kalaitzidis RG. The Role of Melatonin in Chronic Kidney Disease and Its Associated Risk Factors: A New Tool in Our Arsenal? American Journal of Nephrology 2022;53(7):565–574. doi:https://doi.org/10.1159/000525441</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Acuña-Castroviejo D, Escames G, Venegas C et al. Extrapineal melatonin: sources, regulation, and potential functions. Cellular and Molecular Life Sciences 2014;71(16):2997–3025. doi: https://doi.org/10.1007/s00018-014-1579-2</mixed-citation><mixed-citation xml:lang="en">Acuña-Castroviejo D, Escames G, Venegas C et al. Extrapineal melatonin: sources, regulation, and potential functions. Cellular and Molecular Life Sciences 2014;71(16):2997–3025. doi:https://doi.org/10.1007/s00018-014-1579-2</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomedicine &amp; Pharmacotherapy 2006; 60(3):97–108. doi: https://doi.org/10.1016/j.biopha.2006.01.002</mixed-citation><mixed-citation xml:lang="en">Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomedicine &amp; Pharmacotherapy 2006; 60(3):97–108. doi:https://doi.org/10.1016/j.biopha.2006.01.002</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pang SF, Dubocovich ML, Brown GM. Melatonin receptors in peripheral tissues: a new area of melatonin research. Biol Signals 1993;2:177–180</mixed-citation><mixed-citation xml:lang="en">Pang SF, Dubocovich ML, Brown GM. Melatonin receptors in peripheral tissues: a new area of melatonin research. Biol Signals 1993;2:177–180</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin Membrane Receptors in Peripheral tissues: Distribution and Functions. Molecular and Cellular Endocrinology 2012;351(2):152–166. doi: https://doi.org/10.1016/j.mce.2012.01.004</mixed-citation><mixed-citation xml:lang="en">Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin Membrane Receptors in Peripheral tissues: Distribution and Functions. Molecular and Cellular Endocrinology 2012;351(2):152–166. doi:https://doi.org/10.1016/j.mce.2012.01.004</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ramírez-Rodríguez G, Meza I, María Eugenia Hernández, Castillo A, Benítez-King G. Melatonin induced cyclic modulation of vectorial water transport in kidney-derived MDCK cells. Kidney International 2003;63(4):1356–1364. doi: https://doi.org/10.1046/j.1523-1755.2003.00872.x</mixed-citation><mixed-citation xml:lang="en">Ramírez-Rodríguez G, Meza I, María Eugenia Hernández, Castillo A, Benítez-King G. Melatonin induced cyclic modulation of vectorial water transport in kidney-derived MDCK cells. Kidney International 2003;63(4):1356–1364. doi:https://doi.org/10.1046/j.1523-1755.2003.00872.x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Song Y, Tam PC, Poon AM, Brown GM, Pang SF. 2-[125I] iodomelatonin-binding sites in the human kidney and the effect of guanosine 5’-O-(3-thiotriphosphate). The Journal of Clinical Endocrinology &amp; Metabolism 1995;80(5):1560–1565. doi: https://doi.org/10.1210/jcem.80.5.7745000</mixed-citation><mixed-citation xml:lang="en">Song Y, Tam PC, Poon AM, Brown GM, Pang SF. 2-[125I] iodomelatonin-binding sites in the human kidney and the effect of guanosine 5’-O-(3-thiotriphosphate). The Journal of Clinical Endocrinology &amp; Metabolism 1995;80(5):1560–1565. doi:https://doi.org/10.1210/jcem.80.5.7745000</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chan CWY, Song Y, Ailenberg M et al. Studies of Melatonin Effects on Epithelia Using the Human Embryonic Kidney-293 (HEK-293) Cell Line*. Endocrinology 1997;138(11):4732–4739. doi: https://doi.org/10.1210/endo.138.11.5524</mixed-citation><mixed-citation xml:lang="en">Chan CWY, Song Y, Ailenberg M et al. Studies of Melatonin Effects on Epithelia Using the Human Embryonic Kidney-293 (HEK-293) Cell Line*. Endocrinology 1997;138(11):4732–4739. doi: https://doi.org/10.1210/endo.138.11.5524</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Song Y, Chan, Brown GM, Pang SF, Silverman M. Studies of the renal action of melatonin: evidence that the effects are mediated by 37 kDa receptors of the Meli a subtype localized primarily to the basolateral membrane of the proximal tubule. The FASEB Journal 1997;11(1):93–100. doi: https://doi.org/10.1096/fasebj.11.1.9034171</mixed-citation><mixed-citation xml:lang="en">Song Y, Chan, Brown GM, Pang SF, Silverman M. Studies of the renal action of melatonin: evidence that the effects are mediated by 37 kDa receptors of the Meli a subtype localized primarily to the basolateral membrane of the proximal tubule. The FASEB Journal 1997;11(1):93–100. doi: https://doi.org/10.1096/fasebj.11.1.9034171</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Drew J, Williams L, Hannah L, Barrett P, Abramovich D. Melatonin receptors in the human fetal kidney: 2-[125I]iodomelatonin binding sites correlated with expression of Mel1a and Mel1b receptor genes. Journal of Endocrinology 1998;156(2):261–267. doi: https://doi.org/10.1677/joe.0.1560261</mixed-citation><mixed-citation xml:lang="en">Drew J, Williams L, Hannah L, Barrett P, Abramovich D. Melatonin receptors in the human fetal kidney: 2-[125I]iodomelatonin binding sites correlated with expression of Mel1a and Mel1b receptor genes. Journal of Endocrinology 1998;156(2):261–267. doi: https:// doi.org/10.1677/joe.0.1560261</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Жукова ОВ, Виноградова ИА, Горанский АИ. Влияние фармакологической стимуляции мелатониновых рецепторов на функцию почек при старении. Успехи геронтологии 2023;36(1):68–75. doi: 10.34922/AE.2023.36.1.009</mixed-citation><mixed-citation xml:lang="en">Zhukova OV, Vinogradova IA, Goransky AI. Effect of pharmacological stimulation of melatonin receptors on renal function in aging. Adv Gerontol. 2023;36(1):68–75. doi: 10.34922/AE.2023.36.1.009</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kvetnoi IM. Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histochem J 1999;31:1–12</mixed-citation><mixed-citation xml:lang="en">Kvetnoi IM. Extrapineal melatonin: location and role within diffuse neuroendocrine system. Histochem J 1999;31:1–12</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Derlacz RA, Poplawski P, Napierala M et al. Melatonininduced modulation of glucose metabolism in primary cultures of rabbit kidney-cortex tubules. J Pineal Res 2005;38:164–169</mixed-citation><mixed-citation xml:lang="en">Derlacz RA, Poplawski P, Napierala M et al. Melatonininduced modulation of glucose metabolism in primary cultures of rabbit kidney-cortex tubules. J Pineal Res 2005;38:164–169</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tasdemir S, Tasdemir C, Vardi N et al. Combined usage of estrogen and melatonin restores bladder contractility and reduces kidney and bladder damage in ovariectomized and pinealectomized rats. Bratisl Lek Listy 2014;115:345–351</mixed-citation><mixed-citation xml:lang="en">Tasdemir S, Tasdemir C, Vardi N et al. Combined usage of estrogen and melatonin restores bladder contractility and reduces kidney and bladder damage in ovariectomized and pinealectomized rats. Bratisl Lek Listy 2014;115:345–351</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tsuda T, Ide M, Iigo M. Influences of season and of temperature, photoperiod, and subcutaneous melatonin infusion on the glomerular filtration rate of ewes. J Pineal Res 1995;19:166–172</mixed-citation><mixed-citation xml:lang="en">Tsuda T, Ide M, Iigo M. Influences of season and of temperature, photoperiod, and subcutaneous melatonin infusion on the glomerular filtration rate of ewes. J Pineal Res 1995;19:166–172</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Pishak VP, Kokoshuk NI. Renal effects of melatonin in intact and pinealectomized rats. Fiziol Zh 1995;41(5):23–26</mixed-citation><mixed-citation xml:lang="en">Pishak VP, Kokoshuk NI. Renal effects of melatonin in intact and pinealectomized rats. Fiziol Zh 1995;41(5):23–26</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ding S, Lin N, Sheng X et al. Melatonin stabilizes ruptureprone vulnerable plaques via regulating macrophage polarization in a nuclear circadian receptor RORα-dependent manner. 2019;67(2). doi: https://doi.org/10.1111/jpi.12581</mixed-citation><mixed-citation xml:lang="en">Ding S, Lin N, Sheng X et al. Melatonin stabilizes ruptureprone vulnerable plaques via regulating macrophage polarization in a nuclear circadian receptor RORα-dependent manner. 2019;67(2). doi:https://doi.org/10.1111/jpi.12581</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Markowska M, Niemczyk S, Romejko K. Melatonin Treatment in Kidney Diseases. Cells 2023;12(6):838. doi: https://doi.org/10.3390/cells12060838</mixed-citation><mixed-citation xml:lang="en">Markowska M, Niemczyk S, Romejko K. Melatonin Treatment in Kidney Diseases. Cells 2023;12(6):838. doi:https://doi.org/10.3390/cells12060838</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Busch M, Nadal J, Schmid M et al. Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease – cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrology 2016;17(1). doi: https://doi.org/10.1186/s12882-016-0273-z</mixed-citation><mixed-citation xml:lang="en">Busch M, Nadal J, Schmid M et al. Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease – cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrology 2016;17(1). doi:https:// doi.org/10.1186/s12882-016-0273-z</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010;17:4256–4269</mixed-citation><mixed-citation xml:lang="en">Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010;17:4256–4269</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Aluwong T, Sumanu VO, Abdulsalam RA et al. Melatonin and probiotic administration ameliorated hyperglycaemia, oxidative stress, and enhanced cytoprotective effect on beta-cells of diabetic rats. Journal of Diabetes &amp; Metabolic Disorders 2023;22(2): 1537–1549. doi: https://doi.org/10.1007/s40200-023-01284-4</mixed-citation><mixed-citation xml:lang="en">Aluwong T, Sumanu VO, Abdulsalam RA et al. Melatonin and probiotic administration ameliorated hyperglycaemia, oxidative stress, and enhanced cytoprotective effect on beta-cells of diabetic rats. Journal of Diabetes &amp; Metabolic Disorders 2023;22(2): 1537–1549. doi:https://doi.org/10.1007/s40200-023-01284-4</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Alsharif KF, Elmahallawy EK, Alblihd MA et al. Melatonin ameliorates serobiochemical alterations and restores the cardio-nephro diabetic vascular and cellular alterations in streptozotocin-induced diabetic rats. Frontiers in Veterinary Science 2023;10. doi: https://doi.org/10.3389/fvets.2023.1089733</mixed-citation><mixed-citation xml:lang="en">Alsharif KF, Elmahallawy EK, Alblihd MA et al. Melatonin ameliorates serobiochemical alterations and restores the cardio-nephro diabetic vascular and cellular alterations in streptozotocin-induced diabetic rats. Frontiers in Veterinary Science 2023;10. doi:https:// doi.org/10.3389/fvets.2023.1089733</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Motawi TK, Ahmed SA, A Hamed M, El-Maraghy SA, M Aziz W. Melatonin and/or rowatinex attenuate streptozotocininduced diabetic renal injury in rats. Journal of Biomedical Research 2019;33(2):113–121. doi: https://doi.org/10.7555/JBR.31.20160028</mixed-citation><mixed-citation xml:lang="en">Motawi TK, Ahmed SA, A Hamed M, El-Maraghy SA, M Aziz W. Melatonin and/or rowatinex attenuate streptozotocininduced diabetic renal injury in rats. Journal of Biomedical Research 2019;33(2):113–121. doi:https://doi.org/10.7555/JBR.31.20160028</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Luo Q, Cai Y, Zhao Q et al. Renal Protective Effects of Melatonin in Animal Models of Diabetes Mellitus-Related Kidney Damage: A Systematic Review and Meta-Analysis. Journal of Diabetes Research 2022;2022:3770417. doi: https://doi.org/10.1155/2022/3770417</mixed-citation><mixed-citation xml:lang="en">Luo Q, Cai Y, Zhao Q et al. Renal Protective Effects of Melatonin in Animal Models of Diabetes Mellitus-Related Kidney Damage: A Systematic Review and Meta-Analysis. Journal of Diabetes Research 2022;2022:3770417. doi:https://doi.org/10.1155/2022/3770417</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Fan Z, Qi X, Yang W, Xia L, Wu Y. Melatonin Ameliorates Renal Fibrosis Through the Inhibition of NF-κB and TGF-β1/ Smad3 Pathways in db/db Diabetic Mice. Archives of Medical Research 2020;51(6):524–534. doi: https://doi.org/10.1016/j.arcmed.2020.05.008</mixed-citation><mixed-citation xml:lang="en">Fan Z, Qi X, Yang W, Xia L, Wu Y. Melatonin Ameliorates Renal Fibrosis Through the Inhibition of NF-κB and TGF-β1/ Smad3 Pathways in db/db Diabetic Mice. Archives of Medical Research 2020;51(6):524–534. doi:https://doi.org/10.1016/j.arcmed.2020.05.008</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wei J, Wang Y, Qi X, Fan Z, Wu Y. Melatonin ameliorates hyperglycaemia-induced renal inflammation by inhibiting the activation of TLR4 and TGF-β1/Smad3 signalling pathway. Am J Transl Res 2020;12(5):1584–1599. doi: идентификатор DOI, если доступен. PMID: 32509163; PMCID: PMC7270025</mixed-citation><mixed-citation xml:lang="en">Wei J, Wang Y, Qi X, Fan Z, Wu Y. Melatonin ameliorates hyperglycaemia-induced renal inflammation by inhibiting the activation of TLR4 and TGF-β1/Smad3 signalling pathway. Am J Transl Res 2020;12(5):1584–1599. doi: идентификатор DOI, если доступен. PMID: 32509163; PMCID: PMC7270025</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hande Yapislar, Ebru Haciosmanoglu, Turkan Sarioglu, Cem Ekmekcioglu. The melatonin MT2 receptor is involved in the anti-apoptotic effects of melatonin in rats with type 2 diabetes mellitus. Tissue and Cell 2022;76:101763–101763. doi: https://doi.org/10.1016/j.tice.2022.101763</mixed-citation><mixed-citation xml:lang="en">Hande Yapislar, Ebru Haciosmanoglu, Turkan Sarioglu, Cem Ekmekcioglu. The melatonin MT2 receptor is involved in the anti-apoptotic effects of melatonin in rats with type 2 diabetes mellitus. Tissue and Cell 2022;76:101763–101763. doi:https://doi.org/10.1016/j.tice.2022.101763</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Luo N, Wang Y, Ma Y, Liu Y, Liu Z. Melatonin alleviates renal injury in diabetic rats by regulating autophagy. Molecular Medicine Reports 2023;28(5). doi: https://doi.org/10.3892/mmr.2023.13101</mixed-citation><mixed-citation xml:lang="en">Luo N, Wang Y, Ma Y, Liu Y, Liu Z. Melatonin alleviates renal injury in diabetic rats by regulating autophagy. Molecular Medicine Reports 2023;28(5). doi:https://doi.org/10.3892/mmr.2023.13101</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Li J, Li N, Yan S et al. Melatonin attenuates renal fibrosis in diabetic mice by activating the AMPK/PGC1α signaling pathway and rescuing mitochondrial function. Molecular Medicine Reports Published online November 29, 2018. doi: https://doi.org/10.3892/mmr.2018.9708</mixed-citation><mixed-citation xml:lang="en">Li J, Li N, Yan S et al. Melatonin attenuates renal fibrosis in diabetic mice by activating the AMPK/PGC1α signaling pathway and rescuing mitochondrial function. Molecular Medicine Reports Published online November 29, 2018. doi:https://doi.org/10.3892/mmr.2018.9708</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Tang H, Yang M, Liu Y et al. Melatonin alleviates renal injury by activating mitophagy in diabetic nephropathy. Frontiers in Endocrinology 2022;13:889729. doi: https://doi.org/10.3389/fendo.2022.889729</mixed-citation><mixed-citation xml:lang="en">Tang H, Yang M, Liu Y et al. Melatonin alleviates renal injury by activating mitophagy in diabetic nephropathy. Frontiers in Endocrinology 2022;13:889729. doi:https://doi.org/10.3389/fendo.2022.889729</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Siddhi J, Sherkhane B, Kalavala AK, Arruri V, Velayutham R, Kumar A. Melatonin prevents diabetes-induced nephropathy by modulating the AMPK/SIRT1 axis: Focus on autophagy and mitochondrial dysfunction. Cell Biology International 2022;46(12):2142–2157. doi: https://doi.org/10.1002/cbin.11899</mixed-citation><mixed-citation xml:lang="en">Siddhi J, Sherkhane B, Kalavala AK, Arruri V, Velayutham R, Kumar A. Melatonin prevents diabetes-induced nephropathy by modulating the AMPK/SIRT1 axis: Focus on autophagy and mitochondrial dysfunction. Cell Biology International 2022;46(12):2142–2157. doi:https://doi.org/10.1002/cbin.11899</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Agil A, Meriem Chayah, Visiedo L et al. Melatonin Improves Mitochondrial Dynamics and Function in the Kidney of Zücker Diabetic Fatty Rats. Journal of Clinical Medicine 2020;9(9):2916–2916. doi: https://doi.org/10.3390/jcm9092916</mixed-citation><mixed-citation xml:lang="en">Agil A, Meriem Chayah, Visiedo L et al. Melatonin Improves Mitochondrial Dynamics and Function in the Kidney of Zücker Diabetic Fatty Rats. Journal of Clinical Medicine 2020;9(9):2916–2916. doi:https://doi.org/10.3390/jcm9092916</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Fang X, Huang W, Sun Q et al. Melatonin attenuates cellular senescence and apoptosis in diabetic nephropathy by regulating STAT3 phosphorylation. Life Sciences 2023;332:122108–122108. doi: https://doi.org/10.1016/j.lfs.2023.122108</mixed-citation><mixed-citation xml:lang="en">Fang X, Huang W, Sun Q et al. Melatonin attenuates cellular senescence and apoptosis in diabetic nephropathy by regulating STAT3 phosphorylation. Life Sciences 2023;332:122108–122108. doi:https://doi.org/10.1016/j.lfs.2023.122108</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Hajam YA, Rai S, Pandi-Perumal SR, Brown GM, Reiter RJ, Cardinali DP. Co-administration of melatonin and insulin improves diabetic-induced impairment of rat kidney function. Neuroendocrinology Published online October 21, 2021. doi: https://doi.org/10.1159/000520280</mixed-citation><mixed-citation xml:lang="en">Hajam YA, Rai S, Pandi-Perumal SR, Brown GM, Reiter RJ, Cardinali DP. Co-administration of melatonin and insulin improves diabetic-induced impairment of rat kidney function. Neuroendocrinology Published online October 21, 2021. doi:https://doi.org/10.1159/000520280</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Ebaid H, Bashandy SAE, Abdel-Mageed AM, Al-Tamimi J, Hassan I, Alhazza IM. Folic acid and melatonin mitigate diabetic nephropathy in rats via inhibition of oxidative stress. Nutrition &amp; Metabolism 2020;17(1). doi: https://doi.org/10.1186/s12986-019-0419-7</mixed-citation><mixed-citation xml:lang="en">Ebaid H, Bashandy SAE, Abdel-Mageed AM, Al-Tamimi J, Hassan I, Alhazza IM. Folic acid and melatonin mitigate diabetic nephropathy in rats via inhibition of oxidative stress. Nutrition &amp; Metabolism 2020;17(1). doi:https://doi.org/10.1186/s12986-019-0419-7</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Alaa H, Abdelaziz M, Mustafa M et al. RETRACTED ARTICLE: Therapeutic effect of melatonin-loaded chitosan/lecithin nanoparticles on hyperglycemia and pancreatic beta cells regeneration in streptozotocin-induced diabetic rats. Scientific Reports 2023;13(1). doi: https://doi.org/10.1038/s41598-023-36929-0</mixed-citation><mixed-citation xml:lang="en">Alaa H, Abdelaziz M, Mustafa M et al. RETRACTED ARTICLE: Therapeutic effect of melatonin-loaded chitosan/lecithin nanoparticles on hyperglycemia and pancreatic beta cells regeneration in streptozotocin-induced diabetic rats. Scientific Reports 2023;13(1). doi:https://doi.org/10.1038/s41598-023-36929-0</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Mahmoud NM, Elshazly SM, Hassan AA, Soliman E. Agomelatine improves streptozotocin-induced diabetic nephropathy through melatonin receptors/SIRT1 signaling pathway. International Immunopharmacology 2022;115:109646–109646. doi: https://doi.org/10.1016/j.intimp.2022.109646</mixed-citation><mixed-citation xml:lang="en">Mahmoud NM, Elshazly SM, Hassan AA, Soliman E. Agomelatine improves streptozotocin-induced diabetic nephropathy through melatonin receptors/SIRT1 signaling pathway. International Immunopharmacology 2022;115:109646–109646. doi:https://doi.org/10.1016/j.intimp.2022.109646</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Xu YY, Chen T, Ding H, Chen Q, Fan QL. Melatonin inhibits circadian gene DEC1 and TLR2/MyD88/NF-κB signaling pathway to alleviate renal injury in type 2 diabetic mice. Acta Diabetologica 2024;61(11):1455–1474. doi: https://doi.org/10.1007/s00592-024-02312-2</mixed-citation><mixed-citation xml:lang="en">Xu YY, Chen T, Ding H, Chen Q, Fan QL. Melatonin inhibits circadian gene DEC1 and TLR2/MyD88/NF-κB signaling pathway to alleviate renal injury in type 2 diabetic mice. Acta Diabetologica 2024;61(11):1455–1474. doi:https://doi.org/10.1007/s00592-024-02312-2</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Refaa Burhan Altemimi, Ibrahim NN, Nazar LA, Hasan HA, Mastafa Heilo Al-Musawi, Moghadam FM. The Predictive Value of Melatonin Levels for the Development of Diabetic Nephropathy in Men with Type 2 Diabetes Mellitus. Reports of Biochemistry and Molecular Biology 2024;13(3):341–348. doi: https://doi.org/10.61186/rbmb.13.3.341</mixed-citation><mixed-citation xml:lang="en">Refaa Burhan Altemimi, Ibrahim NN, Nazar LA, Hasan HA, Mastafa Heilo Al-Musawi, Moghadam FM. The Predictive Value of Melatonin Levels for the Development of Diabetic Nephropathy in Men with Type 2 Diabetes Mellitus. Reports of Biochemistry and Molecular Biology 2024;13(3):341–348. doi:https://doi.org/10.61186/rbmb.13.3.341</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Daher G, Santos-Bezerra DP, Cavaleiro AM et al. Rs4862705 in the melatonin receptor 1A gene is associated with renal function decline in type 1 diabetes individuals. Frontiers in Endocrinology 2024;15. doi: https://doi.org/10.3389/fendo.2024.1331012</mixed-citation><mixed-citation xml:lang="en">Daher G, Santos-Bezerra DP, Cavaleiro AM et al. Rs4862705 in the melatonin receptor 1A gene is associated with renal function decline in type 1 diabetes individuals. Frontiers in Endocrinology 2024;15. doi:https://doi.org/10.3389/fendo.2024.1331012</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Satari M, Bahmani F, Reiner Z et al. Metabolic and antiinflammatory response to melatonin administration in patients with diabetic nephropathy. Iran J Kidney Dis 2021;1(1):22–30. doi: 33492301</mixed-citation><mixed-citation xml:lang="en">Satari M, Bahmani F, Reiner Z et al. Metabolic and antiinflammatory response to melatonin administration in patients with diabetic nephropathy. Iran J Kidney Dis 2021;1(1):22–30. doi: 33492301</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Kadhim HM, Ismail SH, Hussein KI et al. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. Journal of Pineal Research 2006;41(2):189–193. doi: https://doi.org/10.1111/j.1600-079x.2006.00353.x</mixed-citation><mixed-citation xml:lang="en">Kadhim HM, Ismail SH, Hussein KI et al. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. Journal of Pineal Research 2006;41(2):189–193. doi:https://doi.org/10.1111/j.1600-079x.2006.00353.x</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Sasivimon Promsan, Anusorn Lungkaphin. The roles of melatonin on kidney injury in obese and diabetic conditions. BioFactors 2020;46(4):531–549. doi: https://doi.org/10.1002/biof.1637</mixed-citation><mixed-citation xml:lang="en">Sasivimon Promsan, Anusorn Lungkaphin. The roles of melatonin on kidney injury in obese and diabetic conditions. BioFactors 2020;46(4):531–549. doi:https://doi.org/10.1002/biof.1637</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Afsar B, Afsar RE, Sag AA et al. Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin, and diabetic nephropathy. Clin Kidney J 2020;13(4):522–530. doi:10.1093/ckj/sfz198</mixed-citation><mixed-citation xml:lang="en">Afsar B, Afsar RE, Sag AA et al. Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin, and diabetic nephropathy. Clin Kidney J 2020;13(4):522–530. doi:10.1093/ckj/sfz198</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Z, Wang R, Wang J et al. Melatonin pretreatment on exosomes: Heterogeneity, therapeutic effects, and usage. Frontiers in Immunology 2022;13. doi: https://doi.org/10.3389/fimmu.2022.933736</mixed-citation><mixed-citation xml:lang="en">Zhou Z, Wang R, Wang J et al. Melatonin pretreatment on exosomes: Heterogeneity, therapeutic effects, and usage. Frontiers in Immunology 2022;13. doi:https://doi.org/10.3389/fimmu.2022.933736</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Han YS, Yoon YM, Go G, Lee JH, Lee SH. Melatonin Protects Human Renal Proximal Tubule Epithelial Cells Against High Glucose-Mediated Fibrosis via the Cellular Prion Protein-TGF-β-Smad Signaling Axis. International Journal of Medical Sciences 2020;17(9):1235–1245. doi: https://doi.org/10.7150/ijms.42603</mixed-citation><mixed-citation xml:lang="en">Han YS, Yoon YM, Go G, Lee JH, Lee SH. Melatonin Protects Human Renal Proximal Tubule Epithelial Cells Against High Glucose-Mediated Fibrosis via the Cellular Prion Protein-TGF-β-Smad Signaling Axis. International Journal of Medical Sciences 2020;17(9):1235–1245. doi:https://doi.org/10.7150/ijms.42603</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Pourhanifeh MH, Hosseinzadeh A, Dehdashtian E, Hemati K, Mehrzadi S. Melatonin: new insights on its therapeutic properties in diabetic complications. Diabetology &amp; Metabolic Syndrome 2020;12(1). doi: https://doi.org/10.1186/s13098-020-00537-z</mixed-citation><mixed-citation xml:lang="en">Pourhanifeh MH, Hosseinzadeh A, Dehdashtian E, Hemati K, Mehrzadi S. Melatonin: new insights on its therapeutic properties in diabetic complications. Diabetology &amp; Metabolic Syndrome 2020;12(1). doi:https://doi.org/10.1186/s13098-020-00537-z</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Valdivielso JM, Rodríguez-Puyol D, Pascual J et al. Atherosclerosis in chronic kidney disease: more, less, or just different? Arterioscler Thromb Vasc Biol 2019;39(9):1938–1966. doi: 10.1161/ATVBAHA.119.312808</mixed-citation><mixed-citation xml:lang="en">Valdivielso JM, Rodríguez-Puyol D, Pascual J et al. Atherosclerosis in chronic kidney disease: more, less, or just different? Arterioscler Thromb Vasc Biol 2019;39(9):1938–1966. doi: 10.1161/ATVBAHA.119.312808</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Suh SH, Oh TR, Choi HS et al. Association of Left Ventricular Diastolic Dysfunction With Cardiovascular Outcomes in Patients With Pre-dialysis Chronic Kidney Disease: Findings From KNOW-CKD Study. Frontiers in Cardiovascular Medicine 2022;9. doi: https://doi.org/10.3389/fcvm.2022.844312</mixed-citation><mixed-citation xml:lang="en">Suh SH, Oh TR, Choi HS et al. Association of Left Ventricular Diastolic Dysfunction With Cardiovascular Outcomes in Patients With Pre-dialysis Chronic Kidney Disease: Findings From KNOW-CKD Study. Frontiers in Cardiovascular Medicine 2022;9. doi:https://doi.org/10.3389/fcvm.2022.844312</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang C, Fang X, Zhang H et al. Genetic susceptibility of hypertension induced kidney disease. Physiological Reports 2020;9(1). doi: https://doi.org/10.14814/phy2.14688</mixed-citation><mixed-citation xml:lang="en">Zhang C, Fang X, Zhang H et al. Genetic susceptibility of hypertension induced kidney disease. Physiological Reports 2020;9(1). doi:https://doi.org/10.14814/phy2.14688</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Mennuni S, Rubattu S, Pierelli G et al. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens 2014;28(2):74–79. doi: 10.1038/jhh.2013.47</mixed-citation><mixed-citation xml:lang="en">Mennuni S, Rubattu S, Pierelli G et al. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens 2014;28(2):74–79. doi: 10.1038/jhh.2013.47</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis 2019;74(1):120–131. doi: 10.1053/j.ajkd.2019.01.015</mixed-citation><mixed-citation xml:lang="en">Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis 2019;74(1):120–131. doi: 10.1053/j.ajkd.2019.01.015</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Russcher M, Koch B, Nagtegaal E. The role of melatonin treatment in chronic kidney disease. Front Biosci (Landmark Ed) 2012;17:2644–2656</mixed-citation><mixed-citation xml:lang="en">Russcher M, Koch B, Nagtegaal E. The role of melatonin treatment in chronic kidney disease. Front Biosci (Landmark Ed) 2012;17:2644–2656</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">QIAO YF, GUO WJ, LI L et al. Melatonin attenuates hypertension-induced renal injury partially through inhibiting oxidative stress in rats. Molecular Medicine Reports 2015;13(1):21–26. doi: https://doi.org/10.3892/mmr.2015.4495</mixed-citation><mixed-citation xml:lang="en">QIAO YF, GUO WJ, LI L et al. Melatonin attenuates hypertension- induced renal injury partially through inhibiting oxidative stress in rats. Molecular Medicine Reports 2015;13(1):21–26. doi:https:// doi.org/10.3892/mmr.2015.4495</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">de Souza AVG, Golim MA, Deffune E et al. Evaluation of Renal Protection From High Doses of Melatonin in an Experimental Model of Renal Ischemia and Reperfusion in Hyperglycemic Rats Transplantation Proceedings 2014;46(5):1591–1593. doi: https://doi.org/10.1016/j.transproceed.2014.02.024</mixed-citation><mixed-citation xml:lang="en">de Souza AVG, Golim MA, Deffune E et al. Evaluation of Renal Protection From High Doses of Melatonin in an Experimental Model of Renal Ischemia and Reperfusion in Hyperglycemic Rats Transplantation Proceedings 2014;46(5):1591–1593. doi:https:// doi.org/10.1016/j.transproceed.2014.02.024</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Shan SK, Lin X, Wu F et al. Vascular wall microenvironment: Endothelial cells original exosomes mediated melatonin-suppressed vascular calcification and vascular ageing in a m6A methylation dependent manner. Bioactive Materials 2024;42:52–67. doi: https://doi.org/10.1016/j.bioactmat.2024.08.021</mixed-citation><mixed-citation xml:lang="en">Shan SK, Lin X, Wu F et al. Vascular wall microenvironment: Endothelial cells original exosomes mediated melatonin-suppressed vascular calcification and vascular ageing in a m6A methylation dependent manner. Bioactive Materials 2024;42:52–67. doi:https:// doi.org/10.1016/j.bioactmat.2024.08.021</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H, Tzi Bun NgNote. Hypotensive Activity of the Pineal Indoleamine Hormones Melatonin, 5-Methoxytryptophol and 5-Methoxytryptamine. Pharmacology &amp; Toxicology 2000;86(3):125–128. doi: https://doi.org/10.1034/j.1600-0773.2000.d01-23.x</mixed-citation><mixed-citation xml:lang="en">Wang H, Tzi Bun NgNote. Hypotensive Activity of the Pineal Indoleamine Hormones Melatonin, 5-Methoxytryptophol and 5-Methoxytryptamine. Pharmacology &amp; Toxicology 2000;86(3):125–128. doi:https://doi.org/10.1034/j.1600-0773.2000.d01-23.x</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Ma S, Chen J, Feng J et al. Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition. Oxidative Medicine and Cellular Longevity 2018;2018:1–12. doi: https://doi.org/10.1155/2018/9286458</mixed-citation><mixed-citation xml:lang="en">Ma S, Chen J, Feng J et al. Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition. Oxidative Medicine and Cellular Longevity 2018;2018:1–12. doi:https://doi.org/10.1155/2018/9286458</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Z, Wang X, Zhang R et al. Melatonin attenuates smoking-induced atherosclerosis by activating the Nrf2 pathway via NLRP3 inflammasomes in endothelial cells. Aging 2021; 13(8):11363–11380. doi: https://doi.org/10.18632/aging.202829</mixed-citation><mixed-citation xml:lang="en">Zhao Z, Wang X, Zhang R et al. Melatonin attenuates smoking-induced atherosclerosis by activating the Nrf2 pathway via NLRP3 inflammasomes in endothelial cells. Aging 2021; 13(8):11363–11380. doi:https://doi.org/10.18632/aging.202829</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Amir Ajoolabady, Bi Y, David Julian McClements et al. Melatonin-based therapeutics for atherosclerotic lesions and beyond: Focusing on macrophage mitophagy. Pharmacological Research 2022;176:106072–106072. doi: https://doi.org/10.1016/j.phrs.2022.106072</mixed-citation><mixed-citation xml:lang="en">Amir Ajoolabady, Bi Y, David Julian McClements et al. Melatonin-based therapeutics for atherosclerotic lesions and beyond: Focusing on macrophage mitophagy. Pharmacological Research 2022;176:106072–106072. doi:https://doi.org/10.1016/j.phrs.2022.106072</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004;38:405–416</mixed-citation><mixed-citation xml:lang="en">Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004;38:405–416</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Liu X, Bai X et al. Melatonin prevents endothelial cell pyroptosis via regulation of long noncoding RNA MEG3/miR-223/NLRP3 axis. Journal of Pineal Research 2017;64(2):e12449. doi: https://doi.org/10.1111/jpi.12449</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Liu X, Bai X et al. Melatonin prevents endothelial cell pyroptosis via regulation of long noncoding RNA MEG3/miR-223/NLRP3 axis. Journal of Pineal Research 2017;64(2):e12449. doi:https://doi.org/10.1111/jpi.12449</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta M, Orozco G, Rao M, Gedaly R, Malluche HH, Neyra JA. The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation. Frontiers in Medicine 2022;9. doi: https://doi.org/10.3389/fmed.2022.803016</mixed-citation><mixed-citation xml:lang="en">Gupta M, Orozco G, Rao M, Gedaly R, Malluche HH, Neyra JA. The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation. Frontiers in Medicine 2022;9. doi:https://doi.org/10.3389/fmed.2022.803016</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Huang YS, Lu KC, Chao TK et al. Role of melatonin receptor 1A and pituitary homeobox-1 coexpression in protecting tubular epithelial cells in membranous nephropathy. Journal of Pineal Research 2018;65(1). doi: https://doi.org/10.1111/jpi.12482</mixed-citation><mixed-citation xml:lang="en">Huang YS, Lu KC, Chao TK et al. Role of melatonin receptor 1A and pituitary homeobox-1 coexpression in protecting tubular epithelial cells in membranous nephropathy. Journal of Pineal Research 2018;65(1). doi:https://doi.org/10.1111/jpi.12482</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y, Lu K, Chao H et al. The MTNR1A mRNA is stabilized by the cytoplasmic hnRNPL in renal tubular cells. Journal of Cellular Physiology 2020;236(3):2023–2035. doi: https://doi.org/10.1002/jcp.29988</mixed-citation><mixed-citation xml:lang="en">Huang Y, Lu K, Chao H et al. The MTNR1A mRNA is stabilized by the cytoplasmic hnRNPL in renal tubular cells. Journal of Cellular Physiology 2020;236(3):2023–2035. doi:https://doi.org/10.1002/jcp.29988</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Fu X, Luo ZX, Yin HH et al. Metabolomics study reveals blood biomarkers for early diagnosis of chronic kidney disease and IgA nephropathy: A retrospective cross-sectional study. Clinica Chimica Acta. Published online February 1, 2024:117815–117815. doi: https://doi.org/10.1016/j.cca.2024.117815</mixed-citation><mixed-citation xml:lang="en">Fu X, Luo ZX, Yin HH et al. Metabolomics study reveals blood biomarkers for early diagnosis of chronic kidney disease and IgA nephropathy: A retrospective cross-sectional study. Clinica Chimica Acta. Published online February 1, 2024:117815–117815. doi:https://doi.org/10.1016/j.cca.2024.117815</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">İmamoğlu M, Cay A, Çobanoglu Ü et al. Effects of melatonin on suppression of renal scarring in experimental model of pyelonephritis. Urology 2006;67(6):1315–1319. doi: https://doi.org/10.1016/j.urology.2005.12.013</mixed-citation><mixed-citation xml:lang="en">İmamoğlu M, Cay A, Çobanoglu Ü et al. Effects of melatonin on suppression of renal scarring in experimental model of pyelonephritis. Urology 2006;67(6):1315–1319. doi:https://doi.org/10.1016/j.urology.2005.12.013</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Göksel Şener, Halil Tuğtepe, Ayliz Velioğlu-Öğünç, Şule Çetinel, Nursal Gedik, Yeğen BÇ. Melatonin prevents neutrophil-mediated oxidative injury in Escherichia coli-induced pyelonephritis in rats. Journal of Pineal Research 2006;41(3):220–227. doi: https://doi.org/10.1111/j.1600-079x.2006.00357.x</mixed-citation><mixed-citation xml:lang="en">Göksel Şener, Halil Tuğtepe, Ayliz Velioğlu-Öğünç, Şule Çetinel, Nursal Gedik, Yeğen BÇ. Melatonin prevents neutrophil-mediated oxidative injury in Escherichia coli-induced pyelonephritis in rats. Journal of Pineal Research 2006;41(3):220–227. doi:https://doi.org/10.1111/j.1600-079x.2006.00357.x</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Allameh Z, Salamzadeh J. Use of antioxidants in urinary tract infection. Journal of Research in Pharmacy Practice 2016;5(2):79–85. doi: https://doi.org/10.4103/2279-042X.179567</mixed-citation><mixed-citation xml:lang="en">Allameh Z, Salamzadeh J. Use of antioxidants in urinary tract infection. Journal of Research in Pharmacy Practice 2016;5(2):79–85. doi:https://doi.org/10.4103/2279-042X.179567</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney International 2014;86(5):905–914. doi: https://doi.org/10.1038/ki.2014.49</mixed-citation><mixed-citation xml:lang="en">Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney International 2014;86(5):905–914. doi:https://doi.org/10.1038/ki.2014.49</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira CB, Lima CAD, Vajgel G, Sandrin-Garcia P. The Role of NLRP3 Inflammasome in Lupus Nephritis. International Journal of Molecular Sciences 2021;22(22):12476. doi: https://doi.org/10.3390/ijms222212476</mixed-citation><mixed-citation xml:lang="en">Oliveira CB, Lima CAD, Vajgel G, Sandrin-Garcia P. The Role of NLRP3 Inflammasome in Lupus Nephritis. International Journal of Molecular Sciences 2021;22(22):12476. doi:https://doi.org/10.3390/ijms222212476</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Peng X, Yang T, Liu G, Liu H, Peng Y, He L. Piperine ameliorated lupus nephritis by targeting AMPK-mediated activation of NLRP3 inflammasome. International Immunopharmacology 2018;65:448–457. doi: https://doi.org/10.1016/j.intimp.2018.10.025</mixed-citation><mixed-citation xml:lang="en">Peng X, Yang T, Liu G, Liu H, Peng Y, He L. Piperine ameliorated lupus nephritis by targeting AMPK-mediated activation of NLRP3 inflammasome. International Immunopharmacology 2018;65:448–457. doi:https://doi.org/10.1016/j.intimp.2018.10.025</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Bonomini F, Dos Santos M, Veronese FV, Rezzani R. NLRP3 Inflammasome Modulation by Melatonin Supplementation in Chronic Pristane-Induced Lupus Nephritis. International Journal of Molecular Sciences 2019;20(14):3466. doi: https://doi.org/10.3390/ijms20143466</mixed-citation><mixed-citation xml:lang="en">Bonomini F, Dos Santos M, Veronese FV, Rezzani R. NLRP3 Inflammasome Modulation by Melatonin Supplementation in Chronic Pristane-Induced Lupus Nephritis. International Journal of Molecular Sciences 2019;20(14):3466. doi:https://doi.org/10.3390/ijms20143466</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">dos Santos M, Favero G, Bonomini F et al. Oral supplementation of melatonin protects against lupus nephritis renal injury in a pristane-induced lupus mouse model. Life Sciences 2018;193:242–251. doi: https://doi.org/10.1016/j.lfs.2017.10.038</mixed-citation><mixed-citation xml:lang="en">dos Santos M, Favero G, Bonomini F et al. Oral supplementation of melatonin protects against lupus nephritis renal injury in a pristane-induced lupus mouse model. Life Sciences 2018;193:242–251. doi:https://doi.org/10.1016/j.lfs.2017.10.038</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol 2015;11:76–87</mixed-citation><mixed-citation xml:lang="en">Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol 2015;11:76–87</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu X, Tang L, Mao J et al. Decoding the Mechanism behind the Pathogenesis of the Focal Segmental Glomerulosclerosis. Tang M, ed. Computational and Mathematical Methods in Medicine. 2022;2022:1–15. doi: https://doi.org/10.1155/2022/1941038</mixed-citation><mixed-citation xml:lang="en">Zhu X, Tang L, Mao J et al. Decoding the Mechanism behind the Pathogenesis of the Focal Segmental Glomerulosclerosis. Tang M, ed. Computational and Mathematical Methods in Medicine. 2022;2022:1–15. doi:https://doi.org/10.1155/2022/1941038</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Wu CC, Lu KC, Lin GJ et al. Melatonin enhances endogenous heme oxygenase-1 and represses immune responses to ameliorate experimental murine membranous nephropathy. Journal of pineal research 2012;52(4):460–469. doi: https://doi.org/10.1111/j.1600-079x.2011.00960.x</mixed-citation><mixed-citation xml:lang="en">Wu CC, Lu KC, Lin GJ et al. Melatonin enhances endogenous heme oxygenase-1 and represses immune responses to ameliorate experimental murine membranous nephropathy. Journal of pineal research 2012;52(4):460–469. doi:https://doi.org/10.1111/j.1600-079x.2011.00960.x</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opinion on Therapeutic Targets 2013;17(12):1483–1496. doi: https://doi.org/10.1517/14728222.2013.834890</mixed-citation><mixed-citation xml:lang="en">Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opinion on Therapeutic Targets 2013;17(12):1483–1496. doi:https://doi.org/10.1517/14728222.2013.834890</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Lin YW, Lee LM, Lee WJ et al. Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity. Journal of Pineal Research 2016;60(3):277–290. doi: https://doi.org/10.1111/jpi.12308</mixed-citation><mixed-citation xml:lang="en">Lin YW, Lee LM, Lee WJ et al. Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity. Journal of Pineal Research 2016;60(3):277–290. doi:https://doi.org/10.1111/jpi.12308</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Min K, Kim HS, Park EJ, Kwon TK. Melatonin enhances thapsigargin-induced apoptosis through reactive oxygen speciesmediated upregulation of CCAAT-enhancer-binding protein homologous protein in human renal cancer cells. Journal of Pineal Research 2012;53(1):99–106. doi: https://doi.org/10.1111/j.1600-079x.2012.00975.x</mixed-citation><mixed-citation xml:lang="en">Min K, Kim HS, Park EJ, Kwon TK. Melatonin enhances thapsigargin-induced apoptosis through reactive oxygen speciesmediated upregulation of CCAAT-enhancer-binding protein homologous protein in human renal cancer cells. Journal of Pineal Research 2012;53(1):99–106. doi:https://doi.org/10.1111/j.1600-079x.2012.00975.x</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Kucuktulu E. Protective effect of melatonin against radiation induced nephrotoxicity in rats. Asian Pac J Cancer Prev 2012;13(8):4101–4105. PMID: 23098524</mixed-citation><mixed-citation xml:lang="en">Kucuktulu E. Protective effect of melatonin against radiation induced nephrotoxicity in rats. Asian Pac J Cancer Prev 2012;13(8):4101–4105. PMID: 23098524</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Kapić D, Mornjaković Z, Ćosović E, Šahinović M. A histological study of the effect of exogenous melatonin on gentamicin induced structural alterations of proximal tubules in rats. Biomolecules and Biomedicine 2014;14(1):30–34. doi: https://doi.org/10.17305/bjbms.2014.2293</mixed-citation><mixed-citation xml:lang="en">Kapić D, Mornjaković Z, Ćosović E, Šahinović M. A histological study of the effect of exogenous melatonin on gentamicin induced structural alterations of proximal tubules in rats. Biomolecules and Biomedicine 2014;14(1):30–34. doi:https://doi.org/10.17305/bjbms.2014.2293</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Lee IC, Kim SH, Lee SM et al. Melatonin attenuates gentamicin-induced nephrotoxicity and oxidative stress in rats. Archives of Toxicology 2012;86(10):1527–1536. doi: https://doi.org/10.1007/s00204-012-0849-8</mixed-citation><mixed-citation xml:lang="en">Lee IC, Kim SH, Lee SM et al. Melatonin attenuates gentamicin-induced nephrotoxicity and oxidative stress in rats. Archives of Toxicology 2012;86(10):1527–1536. doi:https://doi.org/10.1007/s00204-012-0849-8</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Morishima I, Matsui H, Hiroaki Mukawa et al. Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats. Life sciences 1998;63(7):511–521. doi: https://doi.org/10.1016/s0024-3205(98)00302-6</mixed-citation><mixed-citation xml:lang="en">Morishima I, Matsui H, Hiroaki Mukawa et al. Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats. Life sciences 1998;63(7):511–521. doi:https://doi.org/10.1016/s0024-3205(98)00302-6</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Parlakpinar H, Ozer MK, Sahna E, Vardi N, Cigremis Y, Acet A. Amikacin-induced acute renal injury in rats: protective role of melatonin. Journal of Pineal Research 2003;35(2):85–90. doi: https://doi.org/10.1034/j.1600-079x.2003.00059.x</mixed-citation><mixed-citation xml:lang="en">Parlakpinar H, Ozer MK, Sahna E, Vardi N, Cigremis Y, Acet A. Amikacin-induced acute renal injury in rats: protective role of melatonin. Journal of Pineal Research 2003;35(2):85–90. doi:https://doi.org/10.1034/j.1600-079x.2003.00059.x</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Yousef JM, Chen G, Hill PA et al. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011;52(11):4044–4049</mixed-citation><mixed-citation xml:lang="en">Yousef JM, Chen G, Hill PA et al. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011;52(11):4044–4049</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Hrenák J, Arendášová K, Rajkovičová R et al. Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats. Physiological Research 2013;62(Suppl 1):S181–189. doi: https://doi.org/10.33549/physiolres.932614</mixed-citation><mixed-citation xml:lang="en">Hrenák J, Arendášová K, Rajkovičová R et al. Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats. Physiological Research 2013;62(Suppl 1):S181–189. doi:https://doi.org/10.33549/physiolres.932614</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Montilla PL, Túnez IF, Muñoz C, Gascón FL, Vicente J. Protective role of melatonin and retinol palmitate in oxidative stress and hyperlipidemic nephropathy induced by adriamycin in rats. Journal of Pineal Research 1998;25(2):86–93. doi: https://doi.org/10.1111/j.1600-079x.1998.tb00544.x</mixed-citation><mixed-citation xml:lang="en">Montilla PL, Túnez IF, Muñoz C, Gascón FL, Vicente J. Protective role of melatonin and retinol palmitate in oxidative stress and hyperlipidemic nephropathy induced by adriamycin in rats. Journal of Pineal Research 1998;25(2):86–93. doi:https://doi.org/10.1111/j.1600-079x.1998.tb00544.x</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Abraham P, Kolli VK, Rabi S. Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Cell Biochemistry and Function 2010;28(5):426–433. doi: https://doi.org/10.1002/cbf.1676</mixed-citation><mixed-citation xml:lang="en">Abraham P, Kolli VK, Rabi S. Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Cell Biochemistry and Function 2010;28(5):426–433. doi:https://doi.org/10.1002/cbf.1676</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Hara M, Yoshida M, Nishijima H et al. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. Journal of Pineal Research 2001;30(3):129–138. doi: https://doi.org/10.1034/j.1600-079x.2001.300301.x</mixed-citation><mixed-citation xml:lang="en">Hara M, Yoshida M, Nishijima H et al. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. Journal of Pineal Research 2001;30(3):129–138. doi:https://doi.org/10.1034/j.160</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Datta M, Majumder R, Chattopadhyay A, Bandyopadhyay D. Protective effect of melatonin in atherosclerotic cardiovascular disease: A comprehensive review. Melatonin Research 2021;4(3):408–430. doi: https://doi.org/10.32794/mr112500102</mixed-citation><mixed-citation xml:lang="en">Datta M, Majumder R, Chattopadhyay A, Bandyopadhyay D. Protective effect of melatonin in atherosclerotic cardiovascular disease: A comprehensive review. Melatonin Research 2021;4(3):408–430. doi:https://doi.org/10.32794/mr112500102</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Stacchiotti A, Ricci F, Rezzani R et al. Tubular Stress Proteins and Nitric Oxide Synthase Expression in Rat Kidney Exposed to Mercuric Chloride and Melatonin. Journal of Histochemistry &amp; Cytochemistry 2006;54(10):1149–1157. doi: https://doi.org/10.1369/jhc.6a6932.2006</mixed-citation><mixed-citation xml:lang="en">Stacchiotti A, Ricci F, Rezzani R et al. Tubular Stress Proteins and Nitric Oxide Synthase Expression in Rat Kidney Exposed to Mercuric Chloride and Melatonin. Journal of Histochemistry &amp; Cytochemistry 2006;54(10):1149–1157. doi:https://doi.org/10.1369/jhc.6a6932.2006</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Mitziev AK. Izmenenie aktivnostyi pereksinnogo okisleniya lipidov kak mekhanizm razvitiya patologii pochek pri deystvii tyazhelykh metallov. Patol Fiziol Eksp Ter 2015;59(2):65–69</mixed-citation><mixed-citation xml:lang="en">Mitziev AK. Izmenenie aktivnostyi pereksinnogo okisleniya lipidov kak mekhanizm razvitiya patologii pochek pri deystvii tyazhelykh metallov. Patol Fiziol Eksp Ter 2015;59(2):65–69</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Ding F, Zhang L, Wu X et al. Melatonin ameliorates renal dysfunction in glyphosate- and hard water-treated mice. Ecotoxicology and Environmental Safety 2022;241:113803–113803. doi: https:// =doi.org/10.1016/j.ecoenv.2022.113803</mixed-citation><mixed-citation xml:lang="en">Ding F, Zhang L, Wu X et al. Melatonin ameliorates renal dysfunction in glyphosate- and hard water-treated mice. Ecotoxicology and Environmental Safety 2022;241:113803–113803. doi:https:// doi.org/10.1016/j.ecoenv.2022.113803</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, Ding F, Wu X et al. Melatonin ameliorates glyphosate-and hard water-induced renal tubular epithelial cell senescence via PINK1-Parkin-dependent mitophagy. Ecotoxicology and Environmental Safety 2023;255:114719. doi: https://doi.org/10.1016/j.ecoenv.2023.114719</mixed-citation><mixed-citation xml:lang="en">Zhang L, Ding F, Wu X et al. Melatonin ameliorates glyphosate-and hard water-induced renal tubular epithelial cell senescence via PINK1-Parkin-dependent mitophagy. Ecotoxicology and Environmental Safety 2023;255:114719. doi:https://doi.org/10.1016/j.ecoenv.2023.114719</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Movahhed SMM. Possible benefits of exogenous melatonin for individuals on dialysis: a narrative review on potential mechanisms and clinical implications. Naunyn-Schmiedeberg’s Archives of Pharmacology. Published online June 7, 2021. doi: https://doi.org/10.1007/s00210-021-02099-x</mixed-citation><mixed-citation xml:lang="en">Movahhed SMM. Possible benefits of exogenous melatonin for individuals on dialysis: a narrative review on potential mechanisms and clinical implications. Naunyn-Schmiedeberg’s Archives of Pharmacology. Published online June 7, 2021. doi:https://doi.org/10.1007/s00210-021-02099-x</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Ostadmohammadi V, Soleimani A, Bahmani F et al. The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Renal Nutrition Published online October 2019. doi: https://doi.org/10.1053/j.jrn.2019.08.003</mixed-citation><mixed-citation xml:lang="en">Ostadmohammadi V, Soleimani A, Bahmani F et al. The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Renal Nutrition Published online October 2019. doi:https://doi.org/10.1053/j.jrn.2019.08.003</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Houssem Marzougui, Imen Ben Dhia, Mezghani I et al. The Synergistic Effect of Intradialytic Concurrent Training and Melatonin Supplementation on Oxidative Stress and Inflammation in Hemodialysis Patients: A Double-Blind Randomized Controlled Trial. Antioxidants 2024;13(11):1290–1290. doi: https://doi.org/10.3390/antiox13111290</mixed-citation><mixed-citation xml:lang="en">Houssem Marzougui, Imen Ben Dhia, Mezghani I et al. The Synergistic Effect of Intradialytic Concurrent Training and Melatonin Supplementation on Oxidative Stress and Inflammation in Hemodialysis Patients: A Double-Blind Randomized Controlled Trial. Antioxidants 2024;13(11):1290–1290. doi:https://doi.org/10.3390/antiox13111290</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Houssem Marzougui, Hammouda O, Imen Ben Dhia et al. Melatonin ingestion before intradialytic exercise improves immune responses in hemodialysis patients. International Urology and Nephrology 2020;53(3):553–562. doi: https://doi.org/10.1007/s11255-020-02643-3</mixed-citation><mixed-citation xml:lang="en">Houssem Marzougui, Hammouda O, Imen Ben Dhia et al. Melatonin ingestion before intradialytic exercise improves immune responses in hemodialysis patients. International Urology and Nephrology 2020;53(3):553–562. doi:https://doi.org/10.1007/s11255-020-02643-3</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Labonia W, Rubio D, Arias C. Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients. Nephrology 2005;10(6):583–587. doi: https://doi.org/10.1111/j.1440-1797.2005.00488.x</mixed-citation><mixed-citation xml:lang="en">Labonia W, Rubio D, Arias C. Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients. Nephrology 2005;10(6):583–587. doi:https://doi.org/10.1111/j.1440-1797.2005.00488.x</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Garwood S. Renal insufficiency after cardiac surgery. Semin Cardiothorac Vasc Anesth 2004;8(3):227–241. doi:10.1177/108925320400800305</mixed-citation><mixed-citation xml:lang="en">Garwood S. Renal insufficiency after cardiac surgery. Semin Cardiothorac Vasc Anesth 2004;8(3):227–241. doi:10.1177/108925320400800305</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998;128(3):194–203. doi:10.7326/0003-4819-128-3-199802010-00005</mixed-citation><mixed-citation xml:lang="en">Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998;128(3):194–203. doi:10.7326/0003-4819-128-3-199802010-00005</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Donohoe J, Venkatachalam MA, Bernard D, Levinsky NG. Tubular leakage and obstruction after renal ischemia: Structuralfunctional correlations. 1978;13(3):208–222. doi: https://doi.org/10.1038/ki.1978.31</mixed-citation><mixed-citation xml:lang="en">Donohoe J, Venkatachalam MA, Bernard D, Levinsky NG. Tubular leakage and obstruction after renal ischemia: Structuralfunctional correlations. 1978;13(3):208–222. doi:https://doi.org/10.1038/ki.1978.31</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Yang C, Sung P, Chiang JY et al. Combined tacrolimus and melatonin effectively protected kidney against acute ischemiareperfusion injury. The FASEB journal 2021;35(6). doi: https://doi.org/10.1096/fj.202100174r</mixed-citation><mixed-citation xml:lang="en">Yang C, Sung P, Chiang JY et al. Combined tacrolimus and melatonin effectively protected kidney against acute ischemiareperfusion injury. The FASEB journal 2021;35(6). doi:https://doi.org/10.1096/fj.202100174r</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Sener G, Sehirli AO, Keyer-Uysal M, Arbak S, Ersoy Y, Yeğen BC. The protective effect of melatonin on renal ischemiareperfusion injury in the rat. J Pineal Res 2002;32(2):120–126. doi:10.1034/j.1600-079x.2002.1848.x</mixed-citation><mixed-citation xml:lang="en">Sener G, Sehirli AO, Keyer-Uysal M, Arbak S, Ersoy Y, Yeğen BC. The protective effect of melatonin on renal ischemiareperfusion injury in the rat. J Pineal Res 2002;32(2):120–126. doi:10.1034/j.1600-079x.2002.1848.x</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Yang J, Liu H, Han S et al. Melatonin pretreatment alleviates renal ischemia-reperfusion injury by promoting autophagic flux via TLR4/MyD88/MEK/ERK/mTORC1 signaling. FASEB J 2020;34(9):12324–12337. doi:10.1096/fj.202001252R</mixed-citation><mixed-citation xml:lang="en">Yang J, Liu H, Han S et al. Melatonin pretreatment alleviates renal ischemia-reperfusion injury by promoting autophagic flux via TLR4/MyD88/MEK/ERK/mTORC1 signaling. FASEB J 2020;34(9):12324–12337. doi:10.1096/fj.202001252R</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Zahran R, Ghozy A, Elkholy SS, El-Taweel F, El-Magd MA. Combination therapy with melatonin, stem cells and extracellular vesicles is effective in limiting renal ischemia-reperfusion injury in a rat model. Int J Urol 2020;27(11):1039–1049. doi:10.1111/iju.14345</mixed-citation><mixed-citation xml:lang="en">Zahran R, Ghozy A, Elkholy SS, El-Taweel F, El-Magd MA. Combination therapy with melatonin, stem cells and extracellular vesicles is effective in limiting renal ischemia-reperfusion injury in a rat model. Int J Urol 2020;27(11):1039–1049. doi:10.1111/iju.14345</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Panah F, Ghorbanihaghjo A, Argani H et al. The effect of oral melatonin on renal ischemia-reperfusion injury in transplant patients: A double-blind, randomized controlled trial. Transpl Immunol 2019;57:101241. doi:10.1016/j.trim.2019.101241</mixed-citation><mixed-citation xml:lang="en">Panah F, Ghorbanihaghjo A, Argani H et al. The effect of oral melatonin on renal ischemia-reperfusion injury in transplant patients: A double-blind, randomized controlled trial. Transpl Immunol 2019;57:101241. doi:10.1016/j.trim.2019.101241</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Anna, Isidor Minović, Martijn van Faassen, et al. Urinary Excretion of 6-Sulfatoxymelatonin, the Main Metabolite of Melatonin, and Mortality in Stable Outpatient Renal Transplant Recipients. Journal of Clinical Medicine 2020;9(2):525–525. doi: https://doi.org/10.3390/jcm9020525</mixed-citation><mixed-citation xml:lang="en">Anna, Isidor Minović, Martijn van Faassen, et al. Urinary Excretion of 6-Sulfatoxymelatonin, the Main Metabolite of Melatonin, and Mortality in Stable Outpatient Renal Transplant Recipients. Journal of Clinical Medicine 2020;9(2):525–525. doi:https://doi.org/10.3390/jcm9020525</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Maung SC, Sara AE, Chapman C, Cohen D, Cukor D. Sleep disorders and chronic kidney disease. World Journal of Nephrology 2016;5(3):224. doi: https://doi.org/10.5527/wjn.v5.i3.224</mixed-citation><mixed-citation xml:lang="en">Maung SC, Sara AE, Chapman C, Cohen D, Cukor D. Sleep disorders and chronic kidney disease. World Journal of Nephrology 2016;5(3):224. doi:https://doi.org/10.5527/wjn.v5.i3.224</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Elder SJ, Pisoni RL, Akizawa T et al. Sleep quality predicts quality of life and mortality risk in haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation 2007;23(3):998–1004. doi: https://doi.org/10.1093/ndt/gfm630</mixed-citation><mixed-citation xml:lang="en">Elder SJ, Pisoni RL, Akizawa T et al. Sleep quality predicts quality of life and mortality risk in haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation 2007;23(3):998–1004. doi:https:// doi.org/10.1093/ndt/gfm630</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Tu CY, Chou YH, Lin YH, Huang WL. Sleep and emotional disturbance in patients with non-dialysis chronic kidney disease. Journal of the Formosan Medical Association 2019;118(6):986–994. doi: https://doi.org/10.1016/j.jfma.2018.10.016</mixed-citation><mixed-citation xml:lang="en">Tu CY, Chou YH, Lin YH, Huang WL. Sleep and emotional disturbance in patients with non-dialysis chronic kidney disease. Journal of the Formosan Medical Association 2019;118(6):986–994. doi:https://doi.org/10.1016/j.jfma.2018.10.016</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Tan LH, Chen PS, Chiang HY et al. Insomnia and Poor Sleep in CKD: A Systematic Review and Meta-analysis. Kidney Medicine 2022;4(5):100458. doi: https://doi.org/10.1016/j.xkme.2022.100458</mixed-citation><mixed-citation xml:lang="en">Tan LH, Chen PS, Chiang HY et al. Insomnia and Poor Sleep in CKD: A Systematic Review and Meta-analysis. Kidney Medicine 2022;4(5):100458. doi:https://doi.org/10.1016/j.xkme.2022.100458</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu CY, Lee CT, Lee YJ et al. Better Sleep Quality and Less Daytime Symptoms in Patients on Evening Hemodialysis: A Questionnaire-based Study. Artificial Organs 2008;32(9):711–716. doi: https://doi.org/10.1111/j.1525-1594.2008.00593.x</mixed-citation><mixed-citation xml:lang="en">Hsu CY, Lee CT, Lee YJ et al. Better Sleep Quality and Less Daytime Symptoms in Patients on Evening Hemodialysis: A Questionnaire-based Study. Artificial Organs 2008;32(9):711–716. doi:https://doi.org/10.1111/j.1525-1594.2008.00593.x</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Novak M, Molnar MZs, Ambrus C et al. Chronic Insomnia in Kidney Transplant Recipients. American Journal of Kidney Diseases 2006;47(4):655–665. doi: https://doi.org/10.1053/j.ajkd.2005.12.035</mixed-citation><mixed-citation xml:lang="en">Novak M, Molnar MZs, Ambrus C et al. Chronic Insomnia in Kidney Transplant Recipients. American Journal of Kidney Diseases 2006;47(4):655–665. doi:https://doi.org/10.1053/j.ajkd.2005.12.035</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Gopal A, Farragher J, Jassal SV, Mucsi I. Sleep Disorders in CKD. American Journal of Kidney Diseases. Published online February 2025. doi: https://doi.org/10.1053/j.ajkd.2024.12.010</mixed-citation><mixed-citation xml:lang="en">Gopal A, Farragher J, Jassal SV, Mucsi I. Sleep Disorders in CKD. American Journal of Kidney Diseases. Published online February 2025. doi:https://doi.org/10.1053/j.ajkd.2024.12.010</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Edalat-Nejad M, Haqhverdi F, Hossein-Tabar T, Ahmadian M. Melatonin improves sleep quality in hemodialysis patients. Indian Journal of Nephrology 2013;23(4):264. doi: https://doi.org/10.4103/0971-4065.114488</mixed-citation><mixed-citation xml:lang="en">Edalat-Nejad M, Haqhverdi F, Hossein-Tabar T, Ahmadian M. Melatonin improves sleep quality in hemodialysis patients. Indian Journal of Nephrology 2013;23(4):264. doi:https:// doi.org/10.4103/0971-4065.114488</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Asghar MS, Ahsan MN, Jawed R et al. A Comparative Study on the Use of Alprazolam and Melatonin for Sleep Disturbances in Hemodialysis Patients. Cureus. Published online November 28, 2020. doi: https://doi.org/10.7759/cureus.11754</mixed-citation><mixed-citation xml:lang="en">Asghar MS, Ahsan MN, Jawed R et al. A Comparative Study on the Use of Alprazolam and Melatonin for Sleep Disturbances in Hemodialysis Patients. Cureus. Published online November 28, 2020. doi:https://doi.org/10.7759/cureus.11754</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Elshahat Ali Yousef, El A, Aya Atef Baddor, Mohammed Abd-Elkader Sobh. A Cross-sectional Study on Pulmonary Hypertension in Patients with Stage 5 Chronic Kidney Disease. Saudi Journal of Kidney Diseases and Transplantation. 2022;33(Suppl 1):S1–S11. doi: https://doi.org/10.4103/1319-2442.367802</mixed-citation><mixed-citation xml:lang="en">Elshahat Ali Yousef, El A, Aya Atef Baddor, Mohammed Abd-Elkader Sobh. A Cross-sectional Study on Pulmonary Hypertension in Patients with Stage 5 Chronic Kidney Disease. Saudi Journal of Kidney Diseases and Transplantation. 2022;33(Suppl 1):S1–S11. doi:https://doi.org/10.4103/1319-2442.367802</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Marzieh SH, Jafari H, Shorofi SA et al. The effect of melatonin on sleep quality and cognitive function of individuals undergoing hemodialysis. Sleep Medicine 2023;111:105–110. doi: https://doi.org/10.1016/j.sleep.2023.09.011</mixed-citation><mixed-citation xml:lang="en">Marzieh SH, Jafari H, Shorofi SA et al. The effect of melatonin on sleep quality and cognitive function of individuals undergoing hemodialysis. Sleep Medicine 2023;111:105–110. doi:https://doi.org/10.1016/j.sleep.2023.09.011</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Ованесов КБ. Значение ретино-эпифизарной системы для психофармакологического эффекта: автореф. дис. … д-ра мед. наук. М., 2004. 44 с. EDN NPXDXR</mixed-citation><mixed-citation xml:lang="en">Ovanesov KB. The Importance of the Retino-Epiphyseal System for the Psychopharmacological Effect: Abstract of a Doctor of Medicine Dissertation. Moscow, 2004. 44 p. EDN NPXDXR</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Арушанян ЭБ, Ованесов КБ, Ованесова ИМ. Сравни- тельное влияние мелатонина и билобила на световосприятие и психофизиологические показатели у лиц, перенесших черепно-мозговую травму. Эксп Клин Фармакол 2007;70(2):20–23. EDN TNJCMT</mixed-citation><mixed-citation xml:lang="en">Arushanyan EB, Ovanesov KB, Ovanesova IM. Comparative influence of melatonin and bilobil on light perception and psychophysiological indices in individuals who suffered traumatic brain injury. Exp Clin Pharmacol 2007;70(2):20–23. EDN TNJCMT</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Шабанов ПД, Арушанян ЕБ, Байрамов АА и др., ред. Психонейроэндокринология-2024: новые тенденции развития. Арт-Экспресс; 2025:544. ISBN 978-5-4391-1025-4. EDN AXGECL</mixed-citation><mixed-citation xml:lang="en">Shabanov PD, Arushanyan EB, Bayramov AA et al., eds. Psychoneuroendocrinology-2024: new development trends. Art-Express; 2025:544. ISBN 978-5-4391-1025-4. EDN AXGECL</mixed-citation></citation-alternatives></ref><ref id="cit129"><label>129</label><citation-alternatives><mixed-citation xml:lang="ru">Арушанян ЭБ, Ованесов КБ. Влияние имипрамина на динамику вынужденного плавания у крыс после энуклеации и пинеалэктомии. Журн. высш. нервн. деят им. И.П. Павлова 1996;46(2):393–395. EDN MOVHHN</mixed-citation><mixed-citation xml:lang="en">Arushanyan EB, Ovanesov KB. Effect of imipramine on the dynamics of forced swimming in rats after enucleation and pinealectomy. I.P. Pavlov Journal of Higher Nervous Activity. 1996;46(2):393–395. EDN MOVHHN</mixed-citation></citation-alternatives></ref><ref id="cit130"><label>130</label><citation-alternatives><mixed-citation xml:lang="ru">Арушанян ЭБ, Ованесов КБ. Антидепрессанты: Учебник для студентов в вопросах и ответах. Ставропольский государственный медицинский университет; 2017:200. EDN YPUIEX</mixed-citation><mixed-citation xml:lang="en">Arushanyan EB, Ovanesov KB. Antidepressants: Textbook for Students in Questions and Answers. Stavropol State Medical University; 2017:200. EDN YPUIEX</mixed-citation></citation-alternatives></ref><ref id="cit131"><label>131</label><citation-alternatives><mixed-citation xml:lang="ru">Арушанян ЕБ, Ованесов КБ. Значение мелатонина для физиологии и патологии глаза. Мед Вестн Сев Кавказа 2016;11(1):126–133. doi:10.14300/mnnc.2016.11017. EDN VVXSZV</mixed-citation><mixed-citation xml:lang="en">Arushanyan EB, Ovanesov KB. Knowledge of melatonin for the physiology and nature of the eyes. Med Vestn North Kavkaz 2016;11(1):126–133. doi:10.14300/mnnc.2016.11017. EDN VVKh-SZV</mixed-citation></citation-alternatives></ref><ref id="cit132"><label>132</label><citation-alternatives><mixed-citation xml:lang="ru">Ованесов КБ, Шабанов ПД. Показатели ретинальной фоточувствительности как объективный показатель выраженности психостимулирующего эффекта. Обзоры по клинической фармакологии и лекарственной терапии 2021;19(3):313–326. doi:10.17816/RCF193313-326</mixed-citation><mixed-citation xml:lang="en">Ovanesov KB, Shabanov PD. Retinal photosensitivity indices as an objective indicator of the severity of the psychostimulating effect. Reviews on Clinical Pharmacology and Drug Therapy 2021;19(3):313–326. doi:10.17816/RCF193313-326</mixed-citation></citation-alternatives></ref><ref id="cit133"><label>133</label><citation-alternatives><mixed-citation xml:lang="ru">Ованесов КБ, Шабанов ПД. Оценка ретинальной фоточувствительности как объективный показатель выраженности психодепримирующего эффекта. Обзоры по клинической фармакологии и лекарственной терапии 2021;19(2): 211–220. doi: 10.17816/RCF192211-220. EDN NYPREG</mixed-citation><mixed-citation xml:lang="en">Ovanesov KB, Shabanov PD. Assessment of retinal photosensitivity as an objective indicator of expression psychodense effect. Reviews on Clinical Pharmacology and Drug Therapy 2021;19(2):211–220. doi: 10.17816/RCF192211-220. EDN NYPREG</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
